ArticleThe Journal of investigative dermatology2026
DNPH1 exerts context-dependent tumor-promoting and -repressing functions during melanoma development.
Article in The Journal of investigative dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Metastatic cutaneous melanoma is a highly lethal and multifarious disease that is driven by the interplay between UV-induced DNA damage and oncogenic lesions, yet enzymes coupling these processes remain incompletely defined. We uncovered the deoxynucleotide hydrolase DNPH1 as an overexpressed melanoma enzyme associated with metastasis and poorer patient survival. DNPH1 overexpression or downregulation in human melanoma cells enhanced or lowered, respectively, their in vitro growth rate. In vivo, Dnph1 loss delayed melanoma initiation and reduced distant metastasis in UV light-exposed, BRAF-V600E-expressing mice. Similarly, Dnph1 knockout in conjunction with oncogenic BRAF-V600E slowed melanoma onset upon ablation of the tumor suppressor TP53. Surprisingly, Dnph1 knockout facilitated growth of tumors after their establishment, indicating stage-specific functions during melanoma development. Mechanistically, UV light triggered the translocation of DNPH1 into the cell nucleus, where it may alter DNA repair pathway choice by suppressing nucleotide excision repair while enhancing homologous recombination and non-homologous end joining. DNPH1 also promoted NF-κB signaling, which may involve cooperation with two interaction partners, ANXA2 and FHL2, in stimulating NF-κB-dependent transcription. Altogether, these findings have identified DNPH1 as a previously unrecognized regulator in the development of cutaneous melanomas where it functions in a context-dependent manner as a tumor promoter or attenuator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.